STAT+: Vertex says its drug successfully reduced marker o...

What’s Happening

So basically Vertex dropped a drug it secured as part of a $4.

9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy. (shocking, we know)

The Readout The Readout STAT Plus: A setback for Roches breast cancer drug By Meghana Keshavan Biotech Biotech STAT Plus: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial By Adam Feuerstein A STAT Examination A STAT Examination STAT Plus: As controversial decisions mount, FDA shuns public advisory meetings By Lizzy Lawrence Adams Take Adams Take STAT Plus: The FDA, urged to avoid controversy, creates a new headache with attack against UniQure By Adam Feuerstein The Readout The Readout STAT Plus: Modernas reset hinges on oncology By Meghana Keshavan STAT Plus: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says By Adam Feuerstein STAT Plus: 5 lessons from Vinay Prasads turbulent tenure at the FDA By Matthew Herper STAT Plus: A new mystery emerges about Epsteins involvement in Harvard genetics study By Megan Molteni STAT Plus: After UnitedHealth moved in, Oregon sought to rein in corporate health care.

Why This Matters

Health experts are weighing in on what this means for people.

This is the kind of health news that affects everyday decisions.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Is this a W or an L? You decide.